Genetic variation of the IL-28B promoter affecting gene expression.
The current standard of care for the treatment of chronic hepatitis C is pegylated interferon-α (PEG-IFNα) and ribavirin (RBV). The treatment achieves a sustained viral clearance in only approximately 50% of patients. Recent whole genome association studies revealed that single nucleotide polymorphi...
Guardado en:
Autores principales: | Masaya Sugiyama, Yasuhito Tanaka, Takaji Wakita, Makoto Nakanishi, Masashi Mizokami |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2011
|
Materias: | |
Acceso en línea: | https://doaj.org/article/e43f1a44991d43adadedf67633e8c03a |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Establishment of a novel hepatitis B virus culture system using immortalized human hepatocytes
por: Yuichi Akahori, et al.
Publicado: (2020) -
Completion of the Entire Hepatitis C Virus Life Cycle in Vero Cells Derived from Monkey Kidney
por: Asako Murayama, et al.
Publicado: (2016) -
Genetic variations of IL-12B, IL-12Rβ1, IL-12Rβ2 in Behcet's disease and VKH syndrome.
por: Xinyu Li, et al.
Publicado: (2014) -
Clinical significance of interferon lambda-3 (IFNλ3)/interleukin 28B (IL28B) in systemic lupus erythematosus patients
por: Fatma H. Abdelraouf, et al.
Publicado: (2022) -
Genetic variation at the CD28 locus and its impact on expansion of pro-inflammatory CD28 negative T cells in healthy individuals
por: Evaggelia Liaskou, et al.
Publicado: (2017)